Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL versus ROBAXIN 750.
CARISOPRODOL vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
250-350 mg orally 3 times daily and at bedtime
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
Clinical Note
moderateCarisoprodol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate."
Clinical Note
moderateCarisoprodol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Ketoconazole
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Ketoconazole can be decreased when combined with Carisoprodol."